Literature DB >> 1506866

MRI findings of multiple sclerosis with acute transverse myelopathy.

T Fukazawa1, K Miyasaka, K Tashiro, T Hamada, F Moriwaka, T Yanagihara, K Hamada.   

Abstract

We classified clinically definite multiple sclerosis (MS) patients who underwent brain MRI with superconductive magnet into 2 subgroups: group A, consisting of 14 patients who had shown acute transverse myelopathy (ATM) during the course of illness; and group B, 35 patients without ATM, and the same neuroradiologist, blinded to clinical profiles of the patients, investigated the MR scans. We analyzed some parameters such as distribution, size, shape and number of the lesions. Although the total number of lesions were similar in each group, and the number of small size or patchy shape solitary lesions were not different, the moderate, large, ovoid or confluent lesions were lower in number in group A, compared with group B. The degree of cerebral white matter lesions and periventricular lesions were higher in group B. Brainstem lesions were significantly less common in group A. These results show characteristic differences in MR-detected, possibly pathological, changes between these 2 groups, and support our previous report that group A may constitute a distinct subgroup in patients with MS.

Entities:  

Mesh:

Year:  1992        PMID: 1506866     DOI: 10.1016/0022-510x(92)90005-6

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  2 in total

1.  An examination of the Apo-1/Fas promoter Mva I polymorphism in Japanese patients with multiple sclerosis.

Authors:  Masaaki Niino; Seiji Kikuchi; Toshiyuki Fukazawa; Ryuji Miyagishi; Ichiro Yabe; Kunio Tashiro
Journal:  BMC Neurol       Date:  2002-08-21       Impact factor: 2.474

2.  Comparison of neurophysiological and MRI findings of patients with multiple sclerosis using oligoclonal band technique.

Authors:  Hamit Y Ellidag; Esin Eren; Nezahat Erdogan; Sabiha Ture; Necat Yilmaz
Journal:  Ann Neurosci       Date:  2013-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.